Information Provided By: 
Fly News Breaks for February 2, 2018
CMRX
Feb 2, 2018 | 07:06 EDT
H.C. Wainwright analyst Edward White started Chimerix with a Buy rating and $10 price target. Investors are unfairly discounting the opportunity in the company's current pipeline, White tells investors in a research note. The analyst notes the pipeline includes brincidofovir, a clinical-stage nucleotide that has demonstrated antiviral activity across all five families of DNA viruses. He points out the stock is currently trading around cash levels.
News For CMRX From the Last 2 Days
There are no results for your query CMRX
